Literature DB >> 24508617

Microglia activation in multiple sclerosis black holes predicts outcome in progressive patients: an in vivo [(11)C](R)-PK11195-PET pilot study.

Paolo Giannetti1, Marios Politis2, Paul Su3, Federico Turkheimer4, Omar Malik5, Shiva Keihaninejad6, Kit Wu7, Richard Reynolds8, Richard Nicholas9, Paola Piccini10.   

Abstract

The pathophysiological correlates and the contribution to persisting disability of hypointense T1-weighted MRI lesions, black holes (BH), in multiple sclerosis (MS) are still unclear. In order to study the in vivo functional correlates of this MRI finding, we used 11C-PK11195 PET (PK-PET) to investigate changes in microglial activity. Ten relapsing and 9 progressive MS subjects had a PK-PET scan and a MRI scan alongside a full clinical assessment, including the expanded disability status scale (EDSS) for evaluation of disability. We studied the PK binding potential of the specifically bound radioligand relative to the non-displaceable radioligand in tissue (BPND) in T1 BHs. Out of a total of 1242 BHs identified, 947 were PK enhancing. The PKBPND was correlated with the EDSS (r=0.818; p<0.05) only in the progressive group. In the relapsing patients there was an inverse correlation between PKBPND and BH total lesion volume in whole brain (r=-0.781; p<0.05). When progressive patients were grouped according to the disability outcome at 2years from the PK-PET scan, the total PKBPND in BHs was found to be a significant outcome predictor of disability (p<0.01). Our findings show that relapsing and progressive patients have heterogeneous patterns of PKBPND in T1 BHs and indicate that BHs are not just "holes" representing loss of axons and myelin, but display inflammatory activity in the form of activated microglia. The significant association between PKBPND, neurological impairment and outcome in progressive subjects supports a role for activated microglia in disability progression.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Black holes; Microglia; Multiple sclerosis; Neurodegeneration; PK11195-PET

Mesh:

Substances:

Year:  2014        PMID: 24508617     DOI: 10.1016/j.nbd.2014.01.018

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  35 in total

Review 1.  The Role of Advanced Magnetic Resonance Imaging Techniques in Multiple Sclerosis Clinical Trials.

Authors:  Kedar R Mahajan; Daniel Ontaneda
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

2.  pHERV-W envelope protein fuels microglial cell-dependent damage of myelinated axons in multiple sclerosis.

Authors:  David Kremer; Joel Gruchot; Vivien Weyers; Lisa Oldemeier; Peter Göttle; Luke Healy; Jeong Ho Jang; Yu Kang T Xu; Christina Volsko; Ranjan Dutta; Bruce D Trapp; Hervé Perron; Hans-Peter Hartung; Patrick Küry
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-18       Impact factor: 11.205

3.  Individual Mapping of Innate Immune Cell Activation Is a Candidate Marker of Patient-Specific Trajectories of Worsening Disability in Multiple Sclerosis.

Authors:  Benedetta Bodini; Emilie Poirion; Matteo Tonietto; Charline Benoit; Raffaele Palladino; Elisabeth Maillart; Erika Portera; Marco Battaglini; Geraldine Bera; Bertrand Kuhnast; Céline Louapre; Michel Bottlaender; Bruno Stankoff
Journal:  J Nucl Med       Date:  2020-01-31       Impact factor: 10.057

4.  Deletion of Arginase 2 Ameliorates Retinal Neurodegeneration in a Mouse Model of Multiple Sclerosis.

Authors:  Chithra D Palani; Abdelrahman Y Fouda; Fang Liu; Zhimin Xu; Eslam Mohamed; Shailedra Giri; Sylvia B Smith; Ruth B Caldwell; S Priya Narayanan
Journal:  Mol Neurobiol       Date:  2019-07-06       Impact factor: 5.590

5.  TSPO PET with [18F]GE-180 sensitively detects focal neuroinflammation in patients with relapsing-remitting multiple sclerosis.

Authors:  Marcus Unterrainer; C Mahler; L Vomacka; S Lindner; J Havla; M Brendel; G Böning; B Ertl-Wagner; T Kümpfel; V M Milenkovic; R Rupprecht; M Kerschensteiner; P Bartenstein; Nathalie L Albert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-03-09       Impact factor: 9.236

6.  Association Between Serum MicroRNAs and Magnetic Resonance Imaging Measures of Multiple Sclerosis Severity.

Authors:  Keren Regev; Brian C Healy; Fariha Khalid; Anu Paul; Renxin Chu; Shahamat Tauhid; Subhash Tummala; Camilo Diaz-Cruz; Radhika Raheja; Maria A Mazzola; Felipe von Glehn; Pia Kivisakk; Sheena L Dupuy; Gloria Kim; Tanuja Chitnis; Howard L Weiner; Roopali Gandhi; Rohit Bakshi
Journal:  JAMA Neurol       Date:  2017-03-01       Impact factor: 18.302

7.  In Response to Letter from Fregonara et al. 2019.

Authors:  Richard Nicholas; David Brooks; David Owen
Journal:  Mol Imaging Biol       Date:  2020-02       Impact factor: 3.488

8.  Translocator positron-emission tomography and magnetic resonance spectroscopic imaging of brain glial cell activation in multiple sclerosis.

Authors:  Gourab Datta; Ines R Violante; Gregory Scott; Karl Zimmerman; Andre Santos-Ribeiro; Eugenii A Rabiner; Roger N Gunn; Omar Malik; Olga Ciccarelli; Richard Nicholas; Paul M Matthews
Journal:  Mult Scler       Date:  2016-12-07       Impact factor: 6.312

9.  Recent imaging advances in neurology.

Authors:  Lorenzo Rocchi; Flavia Niccolini; Marios Politis
Journal:  J Neurol       Date:  2015-03-26       Impact factor: 4.849

10.  Assessment of 18F-PBR-111 in the Cuprizone Mouse Model of Multiple Sclerosis.

Authors:  Valerie L Jewells; Hong Yuan; Joseph R Merrill; Jonathan E Frank; Akhil Patel; Stephanie M Cohen; Ben Giglio; Nana Nikolaishvili Feinberg; Glenn K Matsushima; Zibo Li
Journal:  Diagnostics (Basel)       Date:  2021-04-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.